Half a century of progress against breast cancer can be summed up in two striking numbers. In the 1970s, five‑year survival hovered in the 70% range. Today, thanks to early detection, survival climbs to an upwards of 95%, according to Dr. Alberto Montero, a medical oncologist and clinical director of the Breast Cancer Medical Oncology Program at University Hospitals Seidman Cancer Center.
Why early detection matters
Dr. Montero stresses that the key to these gains is catching cancer early. Mammography remains the gold standard for screening. The National Cancer Institute’s SEER program reports a five‑year relative survival of 91.9% for women diagnosed between 2016 and 2022, compared with roughly 76% for women diagnosed in the mid‑1970s. When cancer is confined to the breast—a scenario that accounts for about 64% of cases—five‑year relative survival reaches 100%, meaning those women are, on average, as likely to be alive five years later as women who never had the disease.
Current screening guidelines
Guidelines from major health bodies now converge on a baseline mammogram around age 40 for women at average risk. The U.S. Preventive Services Task Force lowered its recommended starting age to 40 in April 2024, advising a mammogram every other year through age 74. The American Cancer Society offers the option to begin annual screening at 40, with regular screening for all women starting at 45. High‑risk women—those with a strong family history or known genetic mutations—follow a different, more intensive screening schedule.
Breast cancer is not a single disease
Modern science recognizes at least four molecular subtypes of breast cancer—luminal A, luminal B, HER2‑enriched, and basal‑like (which overlaps heavily with triple‑negative disease). While treatment decisions still hinge primarily on stage, grade, hormone‑receptor status, and HER2 status, these subtypes help clinicians understand the disease’s natural history and tailor therapy.
Genetics play a small role
Only about 5% to 10% of breast cancers are linked to inherited gene mutations, most commonly BRCA1 and BRCA2. Women with a harmful BRCA1/2 change face a lifetime risk of over 60%, compared with about 13% in the general population. In recognition of this, the American Society of Clinical Oncology and the Society of Surgical Oncology now recommend offering BRCA1/2 testing to every patient newly diagnosed at age 65 or younger, and to selected older patients based on family history, ancestry, tumor type, or eligibility for specific drugs.
Personalizing treatment and sparing chemotherapy
Advances in molecular testing also guide treatment intensity. The TAILORx trial, which enrolled 10,273 women with hormone‑receptor‑positive, HER2‑negative, node‑negative tumors, used a 21‑gene assay to stratify risk. Among the 9,719 participants with follow‑up data, 69% fell into an intermediate risk group for whom hormone therapy alone was as effective as hormone therapy plus chemotherapy, with only younger women (age 50 or younger) showing some added benefit from chemotherapy. This shift allows many patients to avoid the toxic side effects of unnecessary chemotherapy.
Takeaway for women
Dr. Montero urges women to understand that most breast cancers are not hereditary and that routine screening can dramatically improve outcomes. By following current mammography guidelines and discussing personal risk factors with a physician, women can benefit from early detection and personalized treatment plans that maximize cure rates while minimizing unnecessary interventions.
Original reporting: KTBS 3 (Shreveport) — read the source article.
